Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Elevai Acquisition [Member]	Common Stock [Member]	Common Stock [Member] Elevai Acquisition [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Elevai Acquisition [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member] Preferred Stock [Member]
Beginning Balance at Dec. 31, 2023	$ 24,749,010		$ 77		$ 83,252,333		$ (58,503,401)	$ 1
Beginning Balance (in Shares) at Dec. 31, 2023			769,686					4,243
Common Stock issued in connection with Notes	848,500		$ 1		848,499
Common Stock issued in connection with Notes (in Shares)			10,957
Stock received from AxoBio Disposition	(23,456,179)		$ (12)		(23,456,166)			$ (1)
Stock received from AxoBio Disposition (in Shares)			(128,178)					(4,243)
Common Stock issued, net of costs	2,687,225		$ 4		2,687,221
Common Stock issued, net of costs (in Shares)			44,382
Stock-based compensation expense	375,169				375,169
Net loss	(6,575,497)	$ (6,575,497)					(6,575,497)
Ending Balance at Jun. 30, 2024	(1,371,772)		$ 70		63,707,056		(65,078,898)
Ending Balance (in Shares) at Jun. 30, 2024			696,847
Beginning Balance at Mar. 31, 2024	(1,391,659)		$ 65		60,382,636		(61,774,360)
Beginning Balance (in Shares) at Mar. 31, 2024			645,369
Common Stock issued in connection with Notes	473,500		$ 1		473,499
Common Stock issued in connection with Notes (in Shares)			7,096
Common Stock issued, net of costs	2,687,225		$ 4		2,687,221
Common Stock issued, net of costs (in Shares)			44,382
Stock-based compensation expense	163,700				163,700
Net loss	(3,304,538)	(3,304,538)					(3,304,538)
Ending Balance at Jun. 30, 2024	(1,371,772)		$ 70		63,707,056		(65,078,898)
Ending Balance (in Shares) at Jun. 30, 2024			696,847
Beginning Balance at Dec. 31, 2024	(4,712,662)		$ 70		64,158,930		(68,871,662)
Beginning Balance (in Shares) at Dec. 31, 2024			696,969
Common Stock issued, net of costs	3,397,476	660,805	$ 74	$ 4	3,397,402	$ 660,801
Common Stock issued, net of costs (in Shares)			748,461	38,308
Stock-based compensation expense	309,152				309,152
Net loss	(3,392,305)	(3,392,305)					(3,392,305)
Ending Balance at Jun. 30, 2025	(3,737,534)		$ 148		68,526,285		(72,263,967)
Ending Balance (in Shares) at Jun. 30, 2025			1,483,738
Beginning Balance at Mar. 31, 2025	(3,805,285)		$ 100		66,572,144		(70,377,529)
Beginning Balance (in Shares) at Mar. 31, 2025			1,004,117
Common Stock issued, net of costs	1,759,866		$ 48		1,759,818
Common Stock issued, net of costs (in Shares)			479,621
Stock-based compensation expense	194,323				194,323
Net loss	(1,886,438)	$ (1,886,438)					(1,886,438)
Ending Balance at Jun. 30, 2025	$ (3,737,534)		$ 148		$ 68,526,285		$ (72,263,967)
Ending Balance (in Shares) at Jun. 30, 2025			1,483,738